

Xenon Pharmaceuticals Inc.  
Form SC 13G  
February 17, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**SCHEDULE 13G**  
**Under the Securities Exchange Act of 1934**

**XENON PHARMACEUTICALS INC.**

**(Name of Issuer)**

**Common Stock Without Par Value**

**(Title of Class of Securities)**

**CUSIP 98420N105**

**December 31, 2014**

**(Date of Event Which Requires Filing of this Statement)**

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

Edgar Filing: Xenon Pharmaceuticals Inc. - Form SC 13G

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1 Name of reporting person

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITY ONLY)

Lipoterx, Ltd.

20-4392231

2 Check the appropriate box if a member of a group

(a)  (b)

3 SEC use only

4 Citizenship or place of organization

Ohio

5 Sole voting power

Number of

shares  None  
6  Shared voting power

beneficially

owned by  1,038,964 (see Item 4)

each 7  Sole dispositive power

reporting

person  None  
8  Shared dispositive power

with

1,038,964 (see Item 4)

9 Aggregate amount beneficially owned by each reporting person

1,038,964 (see Item 4)

10 Check box if the aggregate amount in Row (9) excludes certain shares

11 Percent of class represented by amount in Row (11)

7.33%

12 Type of reporting person

PN

CUSIP No. 98420N105

Page 3 of 9 Pages

1 Name of reporting person

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITY ONLY)

Lipoterx Holdings, LLC

20-4392231

2 Check the appropriate box if a member of a group

(a)  (b)

3 SEC use only

4 Citizenship or place of organization

Ohio

5 Sole voting power

Number of

shares  None  
6  Shared voting power

beneficially

owned by  1,038,964 (see Item 4)

each 7  Sole dispositive power

reporting

person  None  
8  Shared dispositive power

with

1,038,964 (see Item 4)

9 Aggregate amount beneficially owned by each reporting person

1,038,964 (see Item 4)

10 Check box if the aggregate amount in Row (9) excludes certain shares

11 Percent of class represented by amount in Row (11)

7.33%

12 Type of reporting person

PN

1 Name of reporting person

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITY ONLY)

Evan Stein

2 Check the appropriate box if a member of a group

(a)  (b)

3 SEC use only

4 Citizenship or place of organization

United States

5 Sole voting power

Number of

shares 11,250

6 Shared voting power

beneficially

owned by 1,038,964 (see Item 4)

each 7 Sole dispositive power

reporting

person 11,250

8 Shared dispositive power

with

1,038,964 (see Item 4)

9 Aggregate amount beneficially owned by each reporting person

1,050,214 (see Item 4)

10 Check box if the aggregate amount in Row (9) excludes certain shares

11 Percent of class represented by amount in Row (11)

7.41%

12 Type of reporting person

IN



**Item 1.**

- (a) Name of Issuer:  
Xenon Pharmaceuticals Inc. (the Company )
- (b) Address of Issuer's Principal Executive Office:  
200 3650 Gilmore Way  
Burnaby, British Columbia  
Canada V5G 4W8

**Item 2.**

- (a) Name of Persons Filing  
This Schedule 13G is being filed by Lipotex, Ltd. ( Lipotex Ltd. ), Lipotex Holdings, LLC ( Holdings ) and Dr. Evan A. Stein ( Stein ), as joint filers (collectively, the Reporting Persons ). Holdings is the sole general partner of Lipotex Ltd. and Stein is the sole managing member and sole owner of Holdings. The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.
- (b) Address of Principal Office or, if none, Residence:  
The principal business office of each of the Reporting Persons is 25 E Superior St., #4602, Chicago. IL. 60611
- (c) Citizenship  
Please see Item 4 of each cover page.
- (d) Title of Class of Securities  
Common Stock, without par value (the Common Stock )
- (e) CUSIP Number  
98420N105

**Item 3.** If this statement is filed pursuant to Rule 13d-1(b) or 13d-2(b), check whether the person filing is a:

- (a)  Broker or Dealer registered under section 15 of the Act (15 U.S.C. 78o).
- (b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d)  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e)  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
- (h)  A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) " Group, in accordance with §240.13d-1(b)(1)(ii)(J).

**Item 4.** Ownership**Lipoterx Ltd.**

Number of Shares: 1,038,964  
Percentage of Outstanding Shares: 7.33%  
Sole Voting Power: None.  
Shared Voting Power: 1,038,964  
Sole Dispositive Power: None.  
Shared Dispositive Power: 1,038,964

**Holdings**

Number of Shares: 1,038,964  
Percentage of Outstanding Shares: 7.33%  
Sole Voting Power: None.  
Shared Voting Power: 1,038,964  
Sole Dispositive Power: None.  
Shared Dispositive Power: 1,038,964

**Stein**

Number of Shares: 1,050,214  
Percentage of Outstanding Shares: 7.41%  
Sole Voting Power: 11,250  
Shared Voting Power: 1,038,964  
Sole Dispositive Power: 11,250  
Shared Dispositive Power: 1,038,964

Stein is the sole member of Holdings, which has the sole power to vote or to direct the vote, and the sole power to dispose or to direct the disposition of, the 1,038,964 shares of Common Stock owned by Lipoterx, Ltd. For purposes of this Schedule 13G only, the Reporting Persons are reporting shared voting and shared dispositive power over the 1,038,964 shares held by Lipoterx, Ltd. Included within the 11,250 shares of Common Stock for which Stein holds sole voting and sole dispositive power are 686 shares of Common Stock underlying options that are exercisable on January 1, 2016 and 342 shares of Common Stock underlying options that are exercisable on January 1, 2017.

**Item 5.** Ownership of Five Percent or Less of a Class

Not applicable.

**Item 6.** Ownership of more than Five Percent on Behalf of another Person

Not applicable.

**Item 7.** Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Not applicable.

**Item 8.** Identification and Classification of Members of the Group

Not applicable.

**Item 9.** Notice of Dissolution of Group  
Not applicable.

**Item 10.** Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

**Exhibits**

Joint Filing Agreement attached as Exhibit A.

CUSIP No. 98420N105

Page 8 of 9 Pages

**Signature**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 17, 2015

**LIPOTERX, LTD.**

By: Lipotex Holdings, LLC, General Partner

By: /s/ Evan A. Stein  
Evan A. Stein, Manager

**LIPOTERX HOLDINGS, LLC**

By: /s/ Evan A. Stein  
Evan A. Stein, Manager

/s/ Evan A. Stein  
Evan A. Stein

**JOINT FILING AGREEMENT**

**In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned, each referred to herein as a Joint Filer, agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereof) with respect to the beneficial ownership of certain shares of Common Stock of Xenon Pharmaceuticals Inc. and further agree that this Joint Filing Agreement shall be included as an exhibit to such joint filings. The Joint Filers state that they each satisfy the requirements for making a joint filing under Rule 13d-1.**

**LIPOTERX, LTD.**

By: Lipotex Holdings, LLC, General Partner

By: /s/ Evan A. Stein  
Evan A. Stein, Manager

**LIPOTERX HOLDINGS, LLC**

By: /s/ Evan A. Stein  
Evan A. Stein, Manager

/s/ Evan A. Stein  
Evan A. Stein

**Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)**